Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—amoxicillin, moxifloxacin, and rifampicin—used for the treatment of bacterial infections. Each component has a distinct mechanism of action: - **Amoxicillin** is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. - **Moxifloxacin** is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication[3]. - **Rifampicin (rifampin)** is an ansamycin antibiotic that inhibits DNA-dependent RNA polymerase in bacteria[4]. The combination aims to provide broad-spectrum antibacterial activity and may be considered in complex or resistant infections such as tuberculosis (TB), where multidrug regimens are standard. Moxifloxacin plus rifampicin combinations have been studied for TB therapy; they show synergistic effects in suppressing resistance but can be antagonistic regarding bactericidal activity[1][6][7]. Amoxicillin may be included to further broaden the spectrum or address specific resistance patterns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + moxifloxacin + rifampicin.